News
December 26, 2025
Trump, Zelenskyy to Meet Sunday at Mar-a-Lago
President Donald Trump and Ukrainian President Volodymyr Zelenskyy reportedly are expected to meet Sunday in Florida to discuss the U.S. peace plan for Ukraine’s war against Russia.
Trump is expected to host Zelenskyy at Mar-a-Lago as both sides try to finalize terms of a U.S.-backed framework aimed at ending the nearly three-year conflict, Axios reported.
The planned sit-down is being viewed as a major signal that negotiations have advanced, especially after Trump previously suggested he would only meet Zelenskyy if a deal was close.
China Aims for 9 Aircraft Carriers by 2035
China is embarking on the largest aircraft carrier buildup in the Pacific since World War II, with ambitions of adding six carriers to its fleet by 2035, according to a Pentagon report released Tuesday.
The report to Congress, an annual assessment of China’s military and security developments, said the People’s Liberation Army Navy, or PLAN, aims to expand its aircraft carrier force to nine vessels by 2035. That would triple China’s ability to deploy carrier strike groups within the next decade.
The report followed a high-profile demonstration of Beijing’s expanding naval power. China’s newest and most advanced aircraft carrier, the CNS Fujian, sailed through the Taiwan Strait last week. The Pentagon described the carrier’s commissioning and sea trials as a “key modernization development.”
TrumpRx Launch: Major Pharma SHOCKED by Price Cuts
President Trump just slashed prescription drug prices by up to 85% overnight, forcing Big Pharma to match foreign lows or face crippling tariffs—what happens when America finally fights back?
Story Snapshot
- TrumpRx.gov launches as direct-to-consumer platform offering brand-name drugs at Most-Favored-Nation prices from other nations.
- Pfizer signs first deal; Eli Lilly, Novo Nordisk follow, dropping GLP-1 drugs like Ozempic to $350 monthly, trending to $245.
- 100% tariffs on imported drugs start October 1 unless manufacturers build U.S. factories, tying price cuts to American jobs.
- Bypasses insurers and PBMs for immediate uninsured access, with Medicare/Medicaid integrations saving taxpayers billions.
- Five manufacturers committed by November 2025, full rollout early 2026 promises “impossible” reductions.
Trump’s Tariff Hammer Forces Pharma Compliance
President Donald J. Trump posted on Truth Social September 25, 2025, imposing 100% tariffs on imported branded drugs effective October 1 unless companies commit to U.S. manufacturing. Manufacturers faced a stark choice: match prices other developed nations pay or lose U.S. market access. Pfizer struck the first Most-Favored-Nation deal September 30, securing tariff exemptions by pledging domestic investments. This executive leverage revived Trump’s 2020 MFN rule, scrapped by Biden, but escalated with direct threats. American patients stand to gain while factories return home.
Eli Lilly and Novo Nordisk quickly followed, agreeing to TrumpRx pricing for GLP-1 weight loss drugs like Ozempic and Wegovy. These medications dropped from $1,000-$1,350 monthly to $350, with projections to $245. Five total agreements by November 6 secured partial MFN terms and U.S. construction timelines. Common sense dictates this works: tariffs protect American interests, rewarding compliance with exemptions while punishing profiteering.
